Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100
- PMID: 3095664
- DOI: 10.1038/323738a0
Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100
Abstract
Apolipoprotein (apo) B-100, the major protein component in low density lipoprotein (LDL), is the ligand that binds to the LDL receptor. It is important in the metabolism of LDL and elevated plasma levels of LDL-apo B are strongly associated with increased risk of coronary artery disease. Although apo B-100 is of great clinical and biological importance its primary structure has defied chemical elucidation, mainly because of its enormous size, insolubility, and tendency to aggregate. Less than 5% of the apo B-100 sequence has been reported, despite the efforts of many laboratories over the past twenty years. Here we report the complete amino acid sequence of human apo B-100 as deducted by sequence analysis of complementary DNA clones; 2,366 of the 4,536 residues were also confirmed by direct sequencing of apo B-100 tryptic peptides. The distribution of trypsin-accessible and -inaccessible peptides of the protein on LDL is non-random and they can be grouped into 5 hypothetical domains. Of 20 potential N-glycosylation sites identified in the sequence, 13 were found by direct peptide sequencing to be glycosylated, and 4 unglycosylated. Examination of the primary structure of apo B-100 reveals that it contains a large number of long (greater than 70 residues) internal repeats and an even larger number of shorter ones, suggesting that the apo B-100 sequence was derived largely from internal duplications. Finally, using synthetic peptides of a specific region of apo B-100, we have identified a potential LDL receptor-binding domain (residues 3,345-3,381) which can bind to the LDL receptor and suppress 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase activities in cultured human fibroblasts.
Similar articles
-
Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.J Intern Med. 2006 May;259(5):473-80. doi: 10.1111/j.1365-2796.2006.01645.x. J Intern Med. 2006. PMID: 16629853 Review.
-
Familial defective apolipoprotein B-100.Dan Med Bull. 1998 Sep;45(4):370-82. Dan Med Bull. 1998. PMID: 9777289 Review.
-
Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction.Biochemistry. 1998 Sep 15;37(37):12867-74. doi: 10.1021/bi980828m. Biochemistry. 1998. PMID: 9737865
-
Conformationally specific enhancement of receptor-mediated LDL binding and internalization by peptide models of a conserved anionic N-terminal domain of human apolipoprotein E.Biochemistry. 1996 Nov 5;35(44):13975-84. doi: 10.1021/bi960006u. Biochemistry. 1996. PMID: 8909295
-
Complete protein sequence and identification of structural domains of human apolipoprotein B.Nature. 1986 Oct 23-29;323(6090):734-8. doi: 10.1038/323734a0. Nature. 1986. PMID: 3773997
Cited by
-
Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment.Life (Basel). 2023 Jul 27;13(8):1639. doi: 10.3390/life13081639. Life (Basel). 2023. PMID: 37629496 Free PMC article. Review.
-
Prognostic Value of Serum Apolipoprotein B to Apolipoprotein A-I Ratio in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.Oncol Res Treat. 2021;44(9):450-468. doi: 10.1159/000517735. Epub 2021 Aug 11. Oncol Res Treat. 2021. PMID: 34380137 Free PMC article.
-
LDL-mimetic lipid nanoparticles prepared by surface KAT ligation for in vivo MRI of atherosclerosis.Chem Sci. 2020 Oct 7;11(44):11998-12008. doi: 10.1039/d0sc04106h. Chem Sci. 2020. PMID: 34094421 Free PMC article.
-
Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.Int J Nanomedicine. 2019 Sep 11;14:7431-7446. doi: 10.2147/IJN.S215080. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31686815 Free PMC article.
-
Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5. Neurobiol Dis. 2019. PMID: 30849508 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous